• 2015-03-27

    Method of separating, proliferating and differentiating follicular stem cells and the composite product for treatment of baldness

    This patent pertains to human adipose-derived adult stem cells, which are multi-potent stem cells. To be more specific, it concerns human adipose-derived multi-potent adult stem cells, which can be maintained in its undifferentiated state through the formation of spheres and have an excellent proliferation rate, as well as the method of extracting and maintaining the said adult stem cells, the method of differentiation of the said multi-potent adult stem cells into neurocytes, adipocytes, chondrocytes, osteoblasts and insulin-secreting pancreatic beta cells, and the cellular treatment agents, containing the said adult stem cells or differentiated cells, for breast tissue formation and treatment of osteoarthritis, osteoporosis and diabetes.

    The multi-potent stem cells concerned have the ability to differentiate into osteoblasts, neurocytes, astrocytes, adipocytes, chondroblasts or insulin-secreting pancreatic beta cells, despite being adult stem cells, and thus can be used to effectively treat osteoporosis, osteoarthritis, neural diseases and diabetes and to form breast tissue. Also, spheres are formed in a culture medium containing CORM-2 culture so that they can be kept in their undifferentiated state for a long time, and they also have an outstanding proliferation rate, which makes them useful as a cellular therapeutic agent.

    Read more
    • 2015-03-25

    A cellular therapeutic agent containing decidua-derived stem cells for urinary incontinence

    This patent pertains to the cellular therapeutic agent containing decidua- or adipose-derived stem cells for treatment of urinary incontinence. To be more specific, it is regarding the cellular therapeutic agent containing decidua- or adipose-derived stem cells from the placenta or menstrual blood for treatment of urinary incontinence.

    The decidua- or adipose-derived stem cells concerned have the effects of increasing the urinary leak point pressure and improving the contraction power of the urethral sphincter, making them useful as a treatment agent for urinary incontinence.

    Read more
    • 2015-03-25
    Multi-potency of placenta-derived stem cells

    Multi-potency of placenta-derived stem cells

    This patent concerns placenta-derived multi-potent stem cells and the cellular therapeutic agent containing thereof. To be more specific, amniotic, serous and basal decidua- or placenta-derived tissues are cultured in a culture medium containing bFGF, and they have the following characteristics after the culture process:

    (a) Shows positive immunological responses to CD29, CD44, CD73, CD90 and CD105 and negative immunological responses to CD31, CD34, CD45 and HLA-DR;

    (b) Positive immunological responses are shown in relation to OCT4 and SSEA4;

    (c) The stem cells grow after adhering to plastic and are characterized by round and spindle shapes in terms of morphology. Spheres are formed using FM sphere-forming medium so that the stem cells can be maintained in their undifferentiated state.

    (d) This patent concerns the method of manufacturing placenta-derived stem cells with an ability to differentiate into cells derived from the mesodermal, endodermal and ectodermal cells as well as the placenta-derived stem cells that are acquired.

    The multi-potent stem cells concerned have the ability to differentiate into myocytes, vascular endothelial cells, osteoblasts, neurocytes, astrocytes, adipocytes, chondroblasts or insulin-secreting pancreatic beta cells, and thus can be used to effectively treat osteoporosis, osteoarthritis, neural diseases and diabetes and to form breast tissue.

    Read more
    • 2015-03-25

    The method of manufacturing stem cells in a size appropriate for intravascular injections

    This patent concerns the method of manufacturing stem cells in a size, i.e. a diameter of 11 to 16㎛, which is appropriate for intravascular injections. It is also regarding the culture medium used in the manufacture of stem cells in a size appropriate for intravascular injections
    Using this patented method, stem cells can be manufactured in a size that is appropriate for intravascular injections, allowing the stem cells administered into the bloodstream to reach the target tissue area and effectively enhance the effectiveness of activation. Accordingly, it can substantially promote the efficacy of cell therapy in which stem cells are used.

    Read more
    • 2015-03-25

    Method of preventing disintegration and aggregation of stem cells and the related composite product

    This patent concerns the method of preventing disintegration and aggregation of stem cells. It is also regards the stem cell composite product that is characterized by suspension of stem cells in an aspirin solution and is intravenously administered. In addition, it concerns a composite product for the prevention of disintegration and aggregation of stem cells, which characteristically become suspended in an aspirin solution.

    This patented method can prevent disintegration and aggregation of cells during transport and storage, and effectively, allowing the administered stem cells to reach the target tissue area and effectively enhance the effectiveness of activation. Accordingly, it can substantially promote the efficacy of cell therapy in which stem cells are used.

    Read more
    • 2015-03-25

    The method of inducing migration of adipose-derived adult stem cells

    This patent pertains to the migration of adipose-derived adult stem cells. To be more specific, it concerns a new usage of adipose-derived adult stem cells, which can migrate to the body areas affected by diseases more effectively following a pretreatment with a specific type of chemokine or a growth factor.

    Read more
Do NOT follow this link or you will be banned from the site!